Open AccessAbstract CT264: Clinical phase II study of SCO-101 - an inhibitor of SRPK1 and ABCG2 - restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients
Author(s) -
Peter Michael Vestlev,
N. Lindland Roest,
Jakob Hv Schou,
Jan Stenvang,
Nils Brünner
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct264
Subject(s) - folfiri , medicine , irinotecan , tolerability , colorectal cancer , pharmacology , oncology , phases of clinical research , folfox , cancer , toxicity , adverse effect , oxaliplatin